Letter to the Editor Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2024; 30(45): 4859-4863
Published online Dec 7, 2024. doi: 10.3748/wjg.v30.i45.4859
Metabolic syndrome and acute pancreatitis: Current status and future prospects
Ying Quan, The First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Ying Quan, Xiao-Jun Yang, Department of Second Ward of General Surgery, Gansu Province People Hospital, Lanzhou 730000, Gansu Province, China
ORCID number: Xiao-Jun Yang (0000-0003-3770-8451).
Author contributions: Quan Y and Yang XJ contributed to this paper; Quan Y designed the overall concept and outline of the manuscript; Yang XJ contributed to the discussion and design of the manuscript; Quan Y and Yang XJ contributed to the writing, and editing the manuscript, and review of literature.
Supported by The National Health Commission's Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment for The Year 2022, National Health Commission's Master's and Doctoral/Postdoctoral Fund Project, No. NHCDP2022001 (to Yang XJ); and Gansu Provincial People's Hospital Doctoral Supervisor Training Project, No. 22GSSYA-3 (to Yang XJ).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Jun Yang, MD, Associate Professor, Chief Physician, Department of Second Ward of General Surgery, Gansu Province People Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com
Received: September 13, 2024
Revised: October 6, 2024
Accepted: October 29, 2024
Published online: December 7, 2024
Processing time: 61 Days and 7.4 Hours

Abstract

Rising incidence of a complicated disorder with a multifarious etiology is acute pancreatitis. Growing numbers of cases of acute pancreatitis are linked to obesity, hyperlipidemia, hyperglycemia, hypertension, and other metabolic diseases. Trends driven by better living standards and unhealthy lifestyle choices both in China and abroad. Furthermore common diagnosis for many patients is metabolic syndrome. Predicting the adverse effect of metabolic syndrome on the severity and prognosis of acute pancreatitis is a main focus of present clinical research. Our next studies seek to investigate the fundamental causes of this link and create preventative plans meant to lower the incidence of pancreatitis linked to metabolic syndrome and enhance the prognosis.

Key Words: Metabolic syndrome; Acute pancreatitis; Obesity; Hypertension; Hyperlipidemia; Hyperglycaemia

Core Tip: Closely linked with metabolic syndrome, acute pancreatitis has a multifactorial etiology. The combination of several elements of metabolic syndrome could affect the prognosis of acute pancreatitis. Reducing the effect of metabolic syndrome depends on early intervention via lifestyle modification. Still, future studies should focus especially on the development of precision treatment plans and focused pharmacological therapies.



TO THE EDITOR

The primary cause of acute pancreatitis (AP) is the aberrant activation of pancreatic enzymes, which results in digestion of the pancreas and surrounding tissues, so triggering localized edema, necrosis, and pancreatic inflammation[1]. AP has a complex etiology that has been well investigated all around. Gallstones[2], hypertriglyceridemia (HTG)[3], too much alcohol consumption[4], genetic predispositions[5], and drug-induced pancreatitis[6] are the most often occurring causes). Although HTG and alcohol-induced AP mostly affect younger and middle-aged men, biliary pancreatitis is more common among the elderly[7]. Especially, new research indicates that HTG has replaced too much alcohol intake as the second most common cause of AP and that the prevalence of AP connected with metabolic syndrome (MS) is increasing. Changes in eating patterns and better living standards most certainly help to explain this trend[5].

Professor Reaven[8] first proposed MS in 1988, outlining the accumulation of metabolic risk factors including central/abdominal obesity, hyperglycemia, dyslipidemia, and hypertension, which taken together cause systemic organ damage. With patients getting younger from low-fiber, high-calorie diets and sedentary lifestyles, the worldwide frequency of MS is rising[9]. Key component of MS, HTG is closely associated with the onset of AP, sometimes known as HTG-AP[10]. Previous studies have looked at the clinical outcomes of HTG-AP in a cohort of 255 patients using individual MS components including obesity, hyperglycemia, hypertension, and low high-density lipoprotein cholesterol. These investigations show that coexistence of several MS components can aggravate the HTG-AP severity[11]. Still, the exact pathophysiological processes and the evolution of focused therapeutic and preventive strategies remain subjects of active research since they highlight the need of more study to direct clinical management.

CORRELATION MECHANISM BETWEEN MS AND AP

Common systemically inflammatory disease, AP can vary in degree from mild to life-threatening[12]. Many AP patients are obese, and studies point to a relationship between growing obesity rates and AP prevalence that is rising. Moreover, the degree of obesity increases the severity of AP[13]. Many times, seen in obese people is HTG. By means of mechanisms including inhibition of mitochondrial complexes I and V, lowering of ATP levels, release of intracellular calcium ions, and induction of pancreatic acinar cell necrosis, unsaturated fatty acids can induce inflammatory reactions. Furthermore, high levels of free fatty acids can activate lysosomal cathepsin B and trypsinogen, so generating active trypsin and so causing pancreatic inflammation and self-digestion[14]. Numerous clinical studies have linked accumulating adipose tissue, especially visceral adipose tissue, to increased multi-system organ damage and pancreatic necrosis in AP[15]. Released biologically active fat factors by adipose tissue help to control immunity, inflammation, and metabolism. But obesity throws off the equilibrium of these fat components, increasing the risk of obesity-related diseases. The enhanced systemic inflammatory response seen in AP[16] mirrors this imbalance. Studies show that higher levels of adipokines cause chronic inflammation and remodeling of adipose tissue, which finally results in systemic insulin resistance (IR)[17]. The main cause of MS is inflammation (IR), which can result in a range of inflammatory responses[18], lead the body to become hypercoagulable and disturbs the coagulation and fibrinolysis systems, so aggravating AP by ischemia and hypoxia of the pancreatic tissue. Two absolutely important features of diabetes mellitus are hyperglycemia and IR. Based on epidemiological data, diabetes patients may be more prone to acquire AP, but the underlying mechanism is yet unknown[19]. Tumor necrosis factor α, NF-κB and islet amyloid peptide may all affect IR; these then mix with hyperglycemia to increase reactive oxygen species generation in acinar cells and boost lipid peroxidation, which causes AP[20]. People with MS also run more danger of gallstones[21]. While lowered bile acid levels in MS patients promote cholestasis and gallstone formation, which finally results in gallstone-induced pancreatitis, prolonged lipid accumulation can lead to larger and more numerous cholesterol crystals. Though little is known about the link between hypertension and AP incidence, some studies indicate that antihypertensive drugs might raise AP risk in those with hypertension[22].

Many times, in clinical practice, MS patients show several comorbidities, which are connected and contribute to the development and progression of AP[23]. This synergy aggravates general prognosis[24], raises the possibility of AP-related complications, and magnifies local and systemic inflammation. Comparatively to non-MS patients, MS patients have lower survival rates, more frequent local and systemic sequelae, and a higher risk of severe AP according to clinical studies[25]. Patients having both AP and several MS components should thus get more attention in clinical environments. More study is required to fully grasp how MS affects the pathogenesis and prognosis of AP.

TREAMENT MEASURES OF AP ASSOCIATED WITH MS

Key component of MS, HTG greatly influences the start and course of HTG-AP. Apart from being the etiology of AP, HTG is a common outcome of AP since it is usually brought on by stress and inflammatory responses[23]. Dietary changes, insulin treatment, heparin administration, antihyperlipidemic drugs, and plasma exchange[26] are the main therapy modalities used for AP linked with MS. Above all, bad lifestyle choices including binge eating, smoking, too much alcohol, and drug use must be cut off[27]. Management of HTG depends much on a well-balanced diet. A high-fat diet increases MS risk; a diet high in fiber, omega-3 and omega-9 fatty acids, complex carbohydrates, antioxidants, minerals, vitamins, and bioactive compounds (such as polyphenols) can reduce obesity, dyslipidemia, hypertension, and diabetes, so addressing components of MS[28]. Still, pharmacotherapy must start right away. Patients with HTG-AP could gain from anti-lipid drugs in cases when serum triglyceride levels keep increasing. Usually prescribed are fenofibrate and omega-3 fatty acids. Twelve months of omega-3 fatty acid treatment notably lowered glutamyl transpeptidase activity, liver fat, and produced positive changes in the lipid profile of MS patients[29]. Furthermore, under research are new pharmacological compounds aiming at apolipoprotein C-III and angiopoietin-like proteins[30]. Comparatively to a placebo group, a 40-person randomized trial including colchicine found that it greatly reduced inflammatory markers linked with obesity and improved inflammatory outcomes in MS patients[31]. Apart from controlling blood glucose, insulin treatment improves immune response, so lowering the infection risks. Moreover, insulin can raise lipoprotein lipase activity in adipose tissue, so improving the prognosis of AP patients[32,33]. Heparin reduces inflammation by preventing intravascular micro thrombosis, so improving pancreatic microcirculation. It forms a complex with antithrombin III that inhibits trypsin and chymotrypsin activities, so lowering pancreatic inflammation and acting therapeutively[34].

Also used in HTG-AP treatment is plasma exchange, although plasma exchange quickly lowers triglyceride levels, a prospective study of 267 HTG-AP patients found that its clinical advantages, especially with relation to organ failure incidence and duration, remain unclear[35]. Another good choice, especially for AP linked to MS, is bariatric surgery. In obesity-related metabolic diseases, it has been clearly shown to help weight loss, cardiovascular risk, dyslipidemia, nonalcoholic fatty liver disease, and glucose homeostasis[36]. Metabolic surgery can reduce type 2 diabetes by 23%-60%, cause steady weight loss of 20%-30%, and lower cardiovascular risk factors including dyslipidemia and hypertension[37]. When MS-related AP presents itself, timely surgical intervention, such as partial or complete pancreatic resection or drainage tube placement, can improve patient outcomes. Increased free fatty acids can cause acidosis, which releases trypsin and then causes pancreatic tissue autolysis. Early surgery reduces mortality by stopping pancreatic autolysis and the dissolution of surrounding tissues, so improving patient survival[38]. For patients with severe AP complicated by MS, then, a more aggressive approach might produce better therapeutic results. New developments in minimally invasive endoscopic procedures present substitutes for treating MS-associated AP. Researchers have created duodenal mucosal thermal ablation techniques and high-performance metal stents meant to treat metabolic diseases linked to IR. Although more clinical research is required to evaluate its safety and efficacy in human patients, this method, shown in pig models, offers a fresh direction for treating MS-related AP[39].

CLINICAL IMPLICATIONS

There are three primary justifications for the classification of AP associated to Three main factors contribute to the consideration of AP linked with MS as a major clinical issue. First, MS's frequency is gradually rising in China. Second, the second most common cause of AP now is HTG, which has exceeded even high alcohol intake. At last, lifestyle changes and possible pharmacological treatments provide efficient ways for treating AP related to MS as well as for preventing it.

CONCLUSION

Increased degree of AP is much correlated with obesity, HTG, hyperglycemia, hypertension, and other components of MS. While the presence of several elements may aggravate the negative consequences of AP, each individual component can independently influence the course, start, and prognosis of the condition. Patients should start significant dietary and lifestyle changes early on to help to offset these effects. Clinically, improving the prognosis, preventing the start of severe AP, and enabling early diagnosis and treatment of MS depend on the evaluation of risk factors in patients with MS-associated AP. More study is needed to clarify the exact processes driving the evolution of MS-related AP. Furthermore, it is prudent to explore potential pharmacological treatments for MS-related AP, as they may offer patients supplementary therapeutic alternatives.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade C

Novelty: Grade C

Creativity or Innovation: Grade C

Scientific Significance: Grade B

P-Reviewer: Shi Y S-Editor: Li L L-Editor: A P-Editor: Yu HG

References
1.  Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE. Diagnosis and Management of Acute Pancreatitis. Gastroenterology. 2024;167:673-688.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
2.  McDermott J, Kao LS, Keeley JA, Nahmias J, de Virgilio C. Management of Gallstone Pancreatitis: A Review. JAMA Surg. 2024;159:818-825.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
3.  Malick WA, Do R, Rosenson RS. Severe hypertriglyceridemia: Existing and emerging therapies. Pharmacol Ther. 2023;251:108544.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 9]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
4.  Adeniran E, Yadav D, Pandol SJ, Papachristou GI, Buxbaum JL, Pisegna JR, Jeon CY. Intense and Sustained Alcohol Consumption Associated With Acute Pancreatitis Warrants Early Intervention. Gastro Hep Adv. 2024;3:61-63.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
5.  Zhu S, Ding Z. Acute pancreatitis and metabolic syndrome: genetic correlations and causal associations. Endocrine. 2024;84:380-387.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
6.  Li D, Wang H, Qin C, Du D, Wang Y, Du Q, Liu S. Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database. Clin Pharmacol Ther. 2024;115:535-544.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
7.  Mederos MA, Reber HA, Girgis MD. Acute Pancreatitis: A Review. JAMA. 2021;325:382-390.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 123]  [Cited by in F6Publishing: 331]  [Article Influence: 110.3]  [Reference Citation Analysis (1)]
8.  Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5710]  [Cited by in F6Publishing: 5813]  [Article Influence: 161.5]  [Reference Citation Analysis (0)]
9.  Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20:12.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1964]  [Cited by in F6Publishing: 2087]  [Article Influence: 347.8]  [Reference Citation Analysis (0)]
10.  Shen Z, Wang X, Zhen Z, Wang Y, Sun P. Metabolic syndrome components and acute pancreatitis: a case-control study in China. BMC Gastroenterol. 2021;21:17.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 15]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
11.  Fu ZH, Zhao ZY, Liang YB, Cheng DY, Luo JM, Jiang HX, Qin SY. Impact of metabolic syndrome components on clinical outcomes in hypertriglyceridemia-induced acute pancreatitis. World J Gastroenterol. 2024;30:3996-4010.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
12.  Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019;16:479-496.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 218]  [Cited by in F6Publishing: 413]  [Article Influence: 82.6]  [Reference Citation Analysis (0)]
13.  Tian Y, Huang Q, Ren YT, Jiang X, Jiang B. Visceral adipose tissue predicts severity and prognosis of acute pancreatitis in obese patients. Hepatobiliary Pancreat Dis Int. 2024;23:458-462.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
14.  Guo YY, Li HX, Zhang Y, He WH. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med. 2019;27:101-109.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Natu A, Stevens T, Kang L, Yasinow S, Mansoor E, Lopez R, Glessing B, Remer E, Richards T, Gupta A, Chak A, Lee PJW. Visceral Adiposity Predicts Severity of Acute Pancreatitis. Pancreas. 2017;46:776-781.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 33]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
16.  Rafaqat S, Radoman-Vujačić I, Patoulias D, Khurshid H, Klisić A. Adipokines and their role in acute pancreatitis. J Med Biochem. 2024;43:512-527.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
17.  Singh RG, Pendharkar SA, Cervantes A, Cho J, Miranda-Soberanis V, Petrov MS. Abdominal obesity and insulin resistance after an episode of acute pancreatitis. Dig Liver Dis. 2018;50:1081-1087.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 27]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
18.  Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3:1-58.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 112]  [Cited by in F6Publishing: 270]  [Article Influence: 24.5]  [Reference Citation Analysis (0)]
19.  Gillies N, Pendharkar SA, Asrani VM, Mathew J, Windsor JA, Petrov MS. Interleukin-6 is associated with chronic hyperglycemia and insulin resistance in patients after acute pancreatitis. Pancreatology. 2016;16:748-755.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 52]  [Cited by in F6Publishing: 59]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
20.  Solanki NS, Barreto SG, Saccone GT. Acute pancreatitis due to diabetes: the role of hyperglycaemia and insulin resistance. Pancreatology. 2012;12:234-239.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 31]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
21.  Zhu Q, Xing Y, Fu Y, Chen X, Guan L, Liao F, Zhou X. Causal association between metabolic syndrome and cholelithiasis: a Mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1180903.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
22.  Rouette J, Yin H, McDonald EG, Barkun A, Azoulay L. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. Drug Saf. 2022;45:65-74.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Reference Citation Analysis (0)]
23.  Szentesi A, Párniczky A, Vincze Á, Bajor J, Gódi S, Sarlós P, Gede N, Izbéki F, Halász A, Márta K, Dobszai D, Török I, Farkas H, Papp M, Varga M, Hamvas J, Novák J, Mickevicius A, Maldonado ER, Sallinen V, Illés D, Kui B, Erőss B, Czakó L, Takács T, Hegyi P. Multiple Hits in Acute Pancreatitis: Components of Metabolic Syndrome Synergize Each Other's Deteriorating Effects. Front Physiol. 2019;10:1202.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 44]  [Article Influence: 8.8]  [Reference Citation Analysis (0)]
24.  Sawalhi S, Al-Maramhy H, Abdelrahman AI, Allah SE, Al-Jubori S. Does the presence of obesity and/or metabolic syndrome affect the course of acute pancreatitis?: A prospective study. Pancreas. 2014;43:565-570.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 24]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
25.  Mikolasevic I, Milic S, Orlic L, Poropat G, Jakopcic I, Franjic N, Klanac A, Kristo N, Stimac D. Metabolic syndrome and acute pancreatitis. Eur J Intern Med. 2016;32:79-83.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 40]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
26.  Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25:689-694.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 253]  [Cited by in F6Publishing: 270]  [Article Influence: 27.0]  [Reference Citation Analysis (0)]
27.  Zhang Q, Fu Z, Li S, Ding X, Zhang W, Ma R, Zhai Q. Clinical characteristics of three distinct types of pancreatitis with overlapping etiologies: A ten-year retrospective cohort study. Pancreatology. 2023;23:949-956.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
28.  Dayi T, Ozgoren M. Effects of the Mediterranean diet on the components of metabolic syndrome. J Prev Med Hyg. 2022;63:E56-E64.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
29.  Šmíd V, Dvořák K, Šedivý P, Kosek V, Leníček M, Dezortová M, Hajšlová J, Hájek M, Vítek L, Bechyňská K, Brůha R. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun. 2022;6:1336-1349.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 26]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
30.  Gligorijevic N, Stefanovic-Racic M, Kershaw EE. Medical management of hypertriglyceridemia in pancreatitis. Curr Opin Gastroenterol. 2023;39:421-427.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
31.  Demidowich AP, Levine JA, Onyekaba GI, Khan SM, Chen KY, Brady SM, Broadney MM, Yanovski JA. Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. Diabetes Obes Metab. 2019;21:1642-1651.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 22]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
32.  He W, Cai W, Yang X, Camilleri G, Zheng X, Wang Q, Li Y, Mukherjee R, Huang W, Sutton R. Insulin or blood purification treatment for hypertriglyceridaemia-associated acute pancreatitis: A systematic review and meta-analysis. Pancreatology. 2022;22:846-857.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 6]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
33.  Gubensek J. The role of apheresis and insulin therapy in hypertriglyceridemic acute pancreatitis-a concise review. BMC Gastroenterol. 2023;23:341.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 4]  [Reference Citation Analysis (0)]
34.  Patil B, Meena LN, Sharma DC, Agarwal G, Dadhich Y, Gupta G. Impact of low-molecular-weight heparin in the treatment of moderately severe and severe acute pancreatitis; a randomized, single blind, phase 3 control trial. Int J Surg. 2022;101:106621.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 11]  [Reference Citation Analysis (0)]
35.  Cao L, Chen Y, Liu S, Huang W, Wu D, Hong D, Wang Z, Sun Y, Qin K, Guo F, Luo C, Jiao Q, Luo X, Zhou J, Li G, Ye B, Chen T, Liu M, Mao W, Wang L, Li S, Windsor JA, Liu Y, Ke L, Tong Z, Li W; Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG). Early Plasmapheresis Among Patients With Hypertriglyceridemia-Associated Acute Pancreatitis. JAMA Netw Open. 2023;6:e2320802.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 7]  [Reference Citation Analysis (0)]
36.  Cordero P, Li J, Oben JA. Bariatric surgery as a treatment for metabolic syndrome. J R Coll Physicians Edinb. 2017;47:364-368.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 14]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
37.  Hanipah ZN, Schauer PR. Bariatric Surgery as a Long-Term Treatment for Type 2 Diabetes/Metabolic Syndrome. Annu Rev Med. 2020;71:1-15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 13]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
38.  Ambroselli D, Masciulli F, Romano E, Catanzaro G, Besharat ZM, Massari MC, Ferretti E, Migliaccio S, Izzo L, Ritieni A, Grosso M, Formichi C, Dotta F, Frigerio F, Barbiera E, Giusti AM, Ingallina C, Mannina L. New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. Nutrients. 2023;15:640.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 49]  [Article Influence: 49.0]  [Reference Citation Analysis (0)]
39.  Park CS, Park HJ, Park JH, Lee JH, Kee HJ, Park JH, Jo JH, Lee HS, Ku CR, Park JY, Bang S, Song JM, Na K, Kang SK, Jung HY, Chung MJ. Highly functional duodenal stent with photosensitizers enables photodynamic therapy for metabolic syndrome treatment: Feasibility and safety study in a porcine model. APL Bioeng. 2024;8:036103.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]